Analysis: US CPI data release will not lead to a surge in Bitcoin volatility
According to ChainCatcher news, tomorrow's US inflation report will be the focus, and investors will be looking for signals from the Federal Reserve's interest rate path. A series of recent unexpected events have weakened expectations for a rate cut. However, the pricing of Bitcoin options suggests that traders do not expect its volatility to rise significantly following the release of the report.
OrBit Markets, an institutional liquidity provider, said: “The market is pricing this event at an almost negligible premium,” noting that Bitcoin prices may fluctuate less than 2% after the CPI report is released, with almost no additional volatility. SP 500 options pricing reflects relatively high volatility.
10x Research founder Markus Thielen has considered Bitcoin options expiring later this week. His analysis is consistent with OrBit's: "The options expiring on May 17 have an implied volatility of 52.8%, just 2% higher than other options, meaning traders expect a modest rise in volatility after the CPI announcement. However, Realized (historical) volatility remains below 50%, meaning expectations for significant gains or losses are not priced in.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.